Back to top
more

Vertex Pharmaceuticals (VRTX)

(Real Time Quote from BATS)

$463.54 USD

463.54
350,463

+0.39 (0.08%)

Updated Sep 27, 2024 03:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Travere (TVTX) Announces Data on Rare Kidney Disease Drug

by Zacks Equity Research

Travere (TVTX) announces positive interim data from the ongoing study of its investigational candidate, sparsentan, for the treatment of IgAN, a rare kidney disorder. Resultantly, the stock rises

Moderna (MRNA) Begins Rare Disease Study, Inks Supply Agreement

by Zacks Equity Research

Moderna (MRNA) doses first patient in phase I/II study with mRNA-3705 for the treatment of a rare multi-organ disorder. The company also revises the supply agreement with the Canadian Government for its COVID vaccine.

Sesen's (SESN) Bladder Cancer Drug Vicineum Gets CRL From FDA

by Zacks Equity Research

Sesen's (SESN) biologics license application filed for Vicineum to treat BCG-unresponsive non-muscle invasive bladder cancer fails to secure approval. The stock declines resultantly.

Pfizer (PFE) Gets Fast Track Tag for Wilson Disease Candidate

by Zacks Equity Research

The FDA bestows a Fast Track designation to Pfizer (PFE) and partner Vivet Therapeutics' clinical-stage gene therapy, VTX-801, for the treatment of Wilson disease.

Organon's (OGN) Q2 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Organon's (OGN) earnings and revenues beat estimates in the second quarter of 2021. Stock up in pre-market trading.

Perrigo (PRGO) Q2 Earnings Lag, Sales Hurt by Weak Cold Season

by Zacks Equity Research

Perrigo (PRGO) reports dismal second-quarter 2021 results. Stock down.

ChemoCentryx (CCXI) Q2 Loss Wider Than Expected, Sales Down

by Zacks Equity Research

ChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the second quarter and misses on sales.

Axsome (AXSM) Q2 Earnings Top, AXS-05 Approval Likely Delayed

by Zacks Equity Research

Axsome Therapeutics (AXSM) reports narrower-than-expected Q2 loss. Yet, share price falls steeply after it notified of a potential delay in the approval of AXS-05 for major depressive disorder

    QIAGEN (QGEN) Gains FDA's EUA for SARS CoV-2 Antigen Test

    by Zacks Equity Research

    QIAGEN's (QGEN) QIAreach SARS CoV-2 Antigen Test can detect SARS CoV-2 antigens in 2-15 minutes and can process an average of 30 swab samples per hour.

    Viatris (VTRS) Beats on Q2 Earnings & Sales, Raises View

    by Zacks Equity Research

    Viatris (VTRS) beats on Q2 earnings and sales. The company raises annual guidance.

    Bayer's (BAYRY) Q2 Earnings & Revenues Surpass Estimates

    by Zacks Equity Research

    Bayer (BAYRY) beats estimates for both earnings and revenues in the second quarter of 2021.

    Amicus (FOLD) Q2 Earnings & Revenues Top Estimates, Stock Up

    by Zacks Equity Research

    Amicus (FOLD) reports narrower-than-expected Q2 loss. The sales figure also beat estimates. Following encouraging results and positive progress with pipeline candidates, the stock rises.

    Amarin (AMRN) Q2 Earnings Top, Vascepa Strong Despite Generics

    by Zacks Equity Research

    Amarin's (AMRN) Vascepa sales benefit from increased demand in the United States during the second quarter. The drug retains majority market share in its segment amid rising generic competition. Stock up.

    How to Find Strong Buy Medical Stocks Using the Zacks Rank

    by Zacks Equity Research

    The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

    Vertex Pharma and Twilio highlighted as Zacks Bull and Bear of the Day

    by Zacks Equity Research

    Vertex Pharma and Twilio highlighted as Zacks Bull and Bear of the Day

    Kevin Cook headshot

    Bull of the Day: Vertex Pharmaceuticals (VRTX)

    by Kevin Cook

    Scientific innovation in the treatment of cystic fibrosis bolsters success and pipeline confidence

    Horizon's (HZNP) Q2 Earnings and Revenues Beat, Stock Up

    by Zacks Equity Research

    Horizon (HZNP) beats on both earnings and revenues in Q2. Sales soared on account of the relaunch of the thyroid eye disease drug Tepezza. As a result, stock rises.

    Clovis (CLVS) Q2 Earnings Miss, PARP Drug Rubraca Sales Down

    by Zacks Equity Research

    Clovis (CLVS) reports wider-than-expected loss for second-quarter 2021. Sales of the company's sole marketed drug, Rubraca, decreased year over year due to COVID-19 impacts.

    Moderna (MRNA) Q2 Earnings Top, COVID-19 Vaccine Brings $4.2B

    by Zacks Equity Research

    Moderna's (MRNA) COVID-19 vaccine continues to enjoy robust demand. The company delivered 199 million doses of its COVID-19 vaccine during the second quarter.

    Here is Why Growth Investors Should Buy Vertex (VRTX) Now

    by Zacks Equity Research

    Vertex (VRTX) possesses solid growth attributes, which could help it handily outperform the market.

    Deciphera (DCPH) Q2 Loss Wider Than Expected, Revenues Beat

    by Zacks Equity Research

    Deciphera (DCPH) posts wider-than-expected loss in the second quarter due to rising R&D costs. Sales beat estimates on the encouraging uptake of Qinlock.

    Zacks.com featured highlights include: Walmart, Vertex Pharma, Medical Properties Trust, TriNet Group and TriMas Corp

    by Zacks Equity Research

    Zacks.com featured highlights include: Walmart, Vertex Pharma, Medical Properties Trust, TriNet Group and TriMas Corp

    Ultragenyx (RARE) Q2 Loss Widens Y/Y, Revenues Beat Estimates

    by Zacks Equity Research

    Ultragenyx Pharmaceutical's (RARE) Q2 sales increase year over year while loss widens.

    Sanghamitra Saha headshot

    Rising P/E: A Trick to Land on 5 Winning Stocks

    by Sanghamitra Saha

    Want to try a different approach? Tap five stocks with increasing P/E ratios.

    Vertex (VRTX) Q2 Earnings Beat Estimates, 2021 Guidance Up

    by Zacks Equity Research

    Vertex's (VRTX) earnings and sales beat estimates in the second quarter of 2021. The company raises revenue guidance for the year.